In fact, bevacizumab itself might not be the most effective VEGF-targeting drug [21–24] at least in breast cancer, but the investigator-initiated nature of this trial made bevacizumab the only realistic antiangiogenic option for the study. The gene discussed is VEGFA; the disease is breast carcinoma.